Revenue growth has recovered to 14.4% and 7.1% year over year in 2026Q1 and 2026Q2, while gross margin has stayed within roughly 52% to 58% and the 2026Q3 operating margin spike to 74.5% appears non-recurring against an 8.9% to 11.0% run rate.
Envista Holdings Corp (NVST) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 2.88B | 2.72B | 2.51B | 2.57B | 2.57B | 2.51B | 1.93B | 2.28B | 2.84B | 2.81B |
| Revenue Growth % | 9.78% | 8.32% | -2.18% | -0.1% | 2.4% | 30.06% | -15.57% | -19.68% | 1.2% | - |
| Cost of Goods Sold | 1.27B | 1.22B | 1.12B | 1.12B | 1.08B | 1.05B | 856M | 933.1M | 1.23B | 1.18B |
| COGS % of Revenue | - | 44.98% | 44.57% | 43.48% | 42.07% | 41.71% | 44.37% | 40.84% | 43.41% | 42.1% |
| Gross Profit | 1.61B | 1.5B | 1.39B | 1.45B | 1.49B | 1.46B | 1.07B | 1.35B | 1.61B | 1.63B |
| Gross Margin % | 55.97% | 55.02% | 55.43% | 56.52% | 57.93% | 58.29% | 55.63% | 59.16% | 56.59% | 57.9% |
| Gross Profit Growth % | - | 7.52% | -4.06% | -2.55% | 1.78% | 36.28% | -20.61% | -16.02% | -1.1% | - |
| Operating Expenses | 877M | 1.27B | 2.43B | 1.42B | 1.17B | 1.16B | 1.03B | 1.12B | 1.31B | 1.24B |
| OpEx % of Revenue | - | 46.72% | 96.78% | 55.29% | 45.51% | 46.08% | 53.37% | 48.84% | 46.1% | 44.15% |
| Selling, General & Admin | 1.18B | 1.16B | 1.14B | 1.03B | 1.03B | 989.5M | 858.8M | 970.1M | 1.11B | 1.03B |
| SG&A % of Revenue | - | 42.53% | 45.25% | 40.11% | 40.03% | 39.44% | 44.52% | 42.46% | 39.12% | 36.74% |
| Research & Development | 121.8M | 114M | 99.1M | 93.8M | 100.1M | 100.5M | 86.7M | 133.1M | 172M | 172.4M |
| R&D % of Revenue | - | 4.19% | 3.95% | 3.65% | 3.9% | 4.01% | 4.49% | 5.83% | 6.05% | 6.13% |
| Other Operating Expenses | -1000K | 0 | 1.19B | 295.9M | 40.7M | 66.2M | 84.1M | 12.8M | 26.4M | 35.9M |
| Operating Income | 733.8M | 225.7M | -1.04B | 31.5M | 319.2M | 306.2M | 43.5M | 235.7M | 298.4M | 386.6M |
| Operating Margin % | 25.5% | 8.3% | -41.35% | 1.23% | 12.42% | 12.2% | 2.25% | 10.32% | 10.49% | 13.75% |
| Operating Income Growth % | - | 121.74% | -3395.87% | -90.13% | 4.25% | 603.91% | -81.54% | -21.01% | -22.81% | - |
| EBITDA | 883.6M | 341.7M | -915.1M | 194.1M | 481.3M | 458.1M | 206.6M | 403.8M | 428.4M | 508M |
| EBITDA Margin % | 30.7% | 12.56% | -36.45% | 7.56% | 18.73% | 18.26% | 10.71% | 17.67% | 15.06% | 18.07% |
| EBITDA Growth % | 172.88% | 137.34% | -571.46% | -59.67% | 5.06% | 121.73% | -48.84% | -5.74% | -15.67% | - |
| D&A (Non-Cash Add-back) | 149.8M | 116M | 123.1M | 162.6M | 162.1M | 151.9M | 163.1M | 168.1M | 130M | 121.4M |
| EBIT | 703.8M | 213.8M | 156.4M | 327.4M | 359.9M | 372.4M | 127.6M | 248.5M | 324.8M | 422.5M |
| Net Interest Income | -19.4M | -36.6M | -46.4M | -63.4M | -38.4M | -54.1M | -62.5M | -3.5M | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.4M | 36.6M | 46.4M | 63.4M | 38.4M | 54.1M | 62.5M | 3.5M | 0 | 0 |
| Other Income/Expense | -49.4M | -48.5M | -46.5M | -86.4M | -35.3M | -51.7M | -63.5M | -2M | 2.7M | 100K |
| Pretax Income | 684.4M | 177.2M | -1.08B | -54.9M | 283.9M | 254.5M | -20M | 233.7M | 301.1M | 386.7M |
| Pretax Margin % | 23.78% | 6.52% | -43.2% | -2.14% | 11.05% | 10.14% | -1.04% | 10.23% | 10.59% | 13.76% |
| Income Tax | 50.8M | 130.2M | 33.9M | 45.3M | 45.9M | -9M | -62.5M | 49.6M | 70.4M | 85.6M |
| Effective Tax Rate % | 7.42% | 73.48% | -3.13% | -82.51% | 16.17% | -3.54% | 312.5% | 21.22% | 23.38% | 22.14% |
| Net Income | 633.6M | 47M | -1.12B | -100.2M | 243.1M | 340.5M | 33.3M | 217.6M | 230.7M | 301.1M |
| Net Margin % | 22.01% | 1.73% | -44.56% | -3.9% | 9.46% | 13.57% | 1.73% | 9.52% | 8.11% | 10.71% |
| Net Income Growth % | 4041.18% | 104.2% | -1016.37% | -141.22% | -28.61% | 922.52% | -84.7% | -5.68% | -23.38% | - |
| Net Income (Continuing) | 633.6M | 47M | -1.12B | -100.2M | 238M | 263.5M | 42.5M | 184.1M | 230.7M | 301.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 5.1M | 77M | -9.2M | 33.5M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 400K | 400K | 2.6M | 3.3M | 4.1M |
| EPS (Diluted) | 3.88 | 0.28 | -6.50 | -0.60 | 1.34 | 1.48 | 0.26 | 1.35 | 1.80 | 2.35 |
| EPS Growth % | 4353.39% | 104.31% | -983.33% | -144.78% | -9.46% | 469.23% | -80.74% | -25% | -23.4% | - |
| EPS (Basic) | - | 0.28 | -6.50 | -0.60 | 1.46 | 1.63 | 0.27 | 1.35 | 1.80 | 2.35 |
| Diluted Shares Outstanding | 163.4M | 169.2M | 172.2M | 166.9M | 177.6M | 177.6M | 164.1M | 136.4M | 154.6M | 154.6M |
| Basic Shares Outstanding | 160.8M | 168M | 172.2M | 166.9M | 162.9M | 161.2M | 159.6M | 136.2M | 154.6M | 154.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying NVST stock.
For fiscal year 2025, Envista Holdings Corp (NVST) reported total revenue of $2.72B. This represents a 3.3% decline compared to $2.81B in 2017.
Envista Holdings Corp (NVST) is profitable, generating $47.0M in net income for the fiscal year ending 2025 with a net profit margin of 1.7%.
Envista Holdings Corp (NVST) reported an operating income of $225.7M, resulting in an operating profit margin of 8.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Envista Holdings Corp (NVST) generated $1.50B in gross profit for the year, representing a gross profit margin of 55.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Margin sensitivity to pricing and volume
Metrics are mathematically derived from official filings.
Revenue Growth Recovering From Flat Base
Based on reported quarterly figures, Envista's revenue grew 14.4% year over year in 2026Q1 and 7.1% in 2026Q2, following near-flat 2024 comparisons that included a -4.8% decline in 2024Q3.
The reacceleration from roughly -4.4% in 2024Q2 to double-digit growth in early 2026 suggests demand recovery or favorable comparisons rather than a clearly durable structural shift. The reported data does not isolate volume versus pricing contribution, so the sustainability of this trajectory warrants further investigation. Investors should monitor whether the 2026Q3 revenue growth of 3.2% signals a deceleration back toward the low-single-digit range.
Gross Margin Holding in a Narrow Band
As reported in financial statements, Envista's gross margin has stayed within roughly 52% to 58% across the ten quarters, with 2026Q3 printing 57.9%, the highest level in the series.
A band this tight suggests a relatively stable cost structure and some degree of pricing discipline, though the reported figures alone cannot confirm pricing power relative to peers. Compared with Align Technology's 68.3% gross margin, Envista's profile appears structurally lower, which may indicate a different product mix or competitive positioning. The 2026Q3 step-up warrants scrutiny, as a single-quarter improvement may not represent a sustained shift.
Net Income Distorted by Non-Operating Swings
Based on Envista's reported figures, net income swung from a $1.2 billion loss in 2024Q2 to $508.3 million in 2026Q3, while operating income of $515.2 million in the same quarter implies a large non-operating or tax contribution.
The gap between operating income and net income in 2026Q3 is unusually large relative to prior quarters, which suggests items outside core operations may be materially influencing reported earnings. The 2024Q2 loss of roughly $1.2 billion and the negative EPS of -6.69 indicate a one-time or impairment-type charge that the reported data does not explain. Reported EPS growth figures are heavily skewed by these base effects and should not be read as a clean trend.
Stable SG&A Absorbing Most Operating Spend
According to recent SEC filings, Envista's SG&A has run between roughly $263 million and $305 million per quarter, consistently representing the largest operating expense line, while R&D stayed near $24 million to $32 million.
SG&A consuming the majority of the operating cost base suggests that commercial and overhead spending is the primary lever on operating margin. R&D intensity of roughly 4% to 5% of revenue appears modest for a medical technology company, which may indicate limited reliance on near-term product innovation or a reporting classification effect. Expense discipline appears reasonable on the reported figures, though the data does not reveal the drivers behind the SG&A trajectory.
Reported Margin Gains May Not Persist
Based on reported figures, the sharp operating margin expansion to 74.5% in 2026Q3 is an outlier against a 7% to 11% run rate, raising questions about its durability and classification.
A single-quarter operating margin far above the surrounding range is more consistent with a non-recurring gain than with structural improvement, and investors should not extrapolate it. Peers such as Henry Schein and DENTSPLY SIRONA report operating margins of 5.7% and 6.8%, so Envista's underlying run rate appears comparable rather than superior. The main risk is that headline profitability is overstated if these one-time items are not separated from recurring earnings.